Penumbra, Inc. (NYSE:PEN – Get Rating) Director Bridget O’rourke sold 88 shares of Penumbra stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of $135.00, for a total value of $11,880.00. Following the transaction, the director now owns 3,960 shares in the company, valued at approximately $534,600. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Penumbra Price Performance
Shares of NYSE:PEN opened at $139.38 on Monday. Penumbra, Inc. has a fifty-two week low of $114.86 and a fifty-two week high of $293.20. The business has a 50-day moving average of $131.51 and a two-hundred day moving average of $176.80. The stock has a market capitalization of $5.25 billion, a P/E ratio of -819.83 and a beta of 0.70. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.31 and a quick ratio of 3.20.
Penumbra (NYSE:PEN – Get Rating) last announced its quarterly earnings results on Tuesday, May 3rd. The company reported ($0.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.07). Penumbra had a positive return on equity of 1.97% and a negative net margin of 0.83%. The company had revenue of $203.90 million during the quarter, compared to analyst estimates of $195.39 million. During the same period in the prior year, the firm earned $0.27 EPS. Penumbra’s quarterly revenue was up 20.5% on a year-over-year basis. On average, equities research analysts predict that Penumbra, Inc. will post 0.23 EPS for the current fiscal year.
Institutional Trading of Penumbra
Wall Street Analyst Weigh In
A number of research analysts have recently weighed in on PEN shares. BTIG Research lowered their price target on Penumbra from $272.00 to $213.00 and set a “buy” rating on the stock in a report on Monday, July 18th. Truist Financial lowered their price target on Penumbra to $180.00 in a report on Friday, July 22nd. Deutsche Bank Aktiengesellschaft reduced their price objective on Penumbra from $250.00 to $163.00 in a research report on Thursday, July 21st. Wells Fargo & Company reduced their price objective on Penumbra from $321.00 to $265.00 in a research report on Wednesday, May 4th. Finally, Citigroup reduced their price objective on Penumbra from $280.00 to $220.00 in a research report on Tuesday, May 17th. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $222.50.
Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands.
- Get a free copy of the StockNews.com research report on Penumbra (PEN)
- Use These To Find Your Stock’s Support and Resistance Levels
- Is Boeing Stock is Ready for Lift-Off ?
- Elon Musk is Out, But Should You Be In Twitter Stock?
- 3 Earnings Announcements That Could Surprise
- Twitter’s Up For Third Week In A Row: What’s Next For The Stock?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.